RvD1 exerts its effects through binding to specific receptors on the surface of target cells. Two primary receptors identified for RvD1 are the G protein-coupled receptor 32 (GPR32) and the lipoxin A4 receptor (ALX/FPR2). These receptors mediate the anti-inflammatory and pro-resolving actions of RvD1 by activating downstream signaling pathways that modulate gene expression and cellular responses.
